Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy.
Identifieur interne : 002422 ( Ncbi/Merge ); précédent : 002421; suivant : 002423Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy.
Auteurs : X H Zhong [Canada] ; J W Haycock ; K. Shannak ; Y. Robitaille ; J. Fratkin ; A H Koeppen ; O. Hornykiewicz ; S J KishSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1995.
English descriptors
- KwdEn :
- Aged, Dopa Decarboxylase (analysis), Dopa Decarboxylase (metabolism), Dopamine (analysis), Dopamine (metabolism), Humans, Immunoblotting, Middle Aged, Olivopontocerebellar Atrophies (diagnosis), Olivopontocerebellar Atrophies (enzymology), Parkinson Disease (diagnosis), Parkinson Disease (enzymology), Tyrosine 3-Monooxygenase (analysis), Tyrosine 3-Monooxygenase (metabolism), Visual Cortex (chemistry).
- MESH :
- chemical , analysis : Dopa Decarboxylase, Dopamine, Tyrosine 3-Monooxygenase.
- chemical , metabolism : Dopa Decarboxylase, Dopamine, Tyrosine 3-Monooxygenase.
- chemistry : Visual Cortex.
- diagnosis : Olivopontocerebellar Atrophies, Parkinson Disease.
- enzymology : Olivopontocerebellar Atrophies, Parkinson Disease.
- Aged, Humans, Immunoblotting, Middle Aged.
Abstract
We measured the levels of dopamine, tyrosine hydroxylase (TH) protein, and dihydroxyphenylalanine (DOPA) decarboxylase (DDC) protein in the striatum of 10 patients with idiopathic Parkinson's disease (PD) and 23 patients with dominantly inherited olivopontocerebellar atrophy (OPCA). The levels of dopamine were markedly reduced (2% of control) in the striatum of the patients with PD, whereas striatal dopamine in the patients with OPCA ranged from normal (> 60% of control) to moderately reduced (20-60% of control) to severely depleted (< 20% of control). Both TH and DDC protein levels were significantly lower than those of the controls in the striatum of all of the patients with PD and in the subgroup of patients with OPCA having severely depleted dopamine. In contradistinction, TH but not DDC protein levels were reduced in those patients with OPCA having moderately reduced dopamine levels. This suggests that in the early stage of nigrostriatal dopamine neurone degeneration, DDC levels may be less susceptible to neurodegenerative influences than is TH synthesis or, alternatively, DDC synthesis may be more aggressively upregulated. Unexpectedly, from the blot immunolabeling analysis an additional DDC-immunoreactive band of slightly lower apparent molecular mass was detected in two of the patients with PD and in 12 of the patients with OPCA. This additional DDC band, which was not present in any of the control subjects, may reflect posttranslational modification(s) of DDC related to the neurodegenerative process.
DOI: 10.1002/mds.870100104
PubMed: 7885342
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001936
- to stream PubMed, to step Curation: 001936
- to stream PubMed, to step Checkpoint: 001936
Links to Exploration step
pubmed:7885342Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy.</title><author><name sortKey="Zhong, X H" sort="Zhong, X H" uniqKey="Zhong X" first="X H" last="Zhong">X H Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Haycock, J W" sort="Haycock, J W" uniqKey="Haycock J" first="J W" last="Haycock">J W Haycock</name></author><author><name sortKey="Shannak, K" sort="Shannak, K" uniqKey="Shannak K" first="K" last="Shannak">K. Shannak</name></author><author><name sortKey="Robitaille, Y" sort="Robitaille, Y" uniqKey="Robitaille Y" first="Y" last="Robitaille">Y. Robitaille</name></author><author><name sortKey="Fratkin, J" sort="Fratkin, J" uniqKey="Fratkin J" first="J" last="Fratkin">J. Fratkin</name></author><author><name sortKey="Koeppen, A H" sort="Koeppen, A H" uniqKey="Koeppen A" first="A H" last="Koeppen">A H Koeppen</name></author><author><name sortKey="Hornykiewicz, O" sort="Hornykiewicz, O" uniqKey="Hornykiewicz O" first="O" last="Hornykiewicz">O. Hornykiewicz</name></author><author><name sortKey="Kish, S J" sort="Kish, S J" uniqKey="Kish S" first="S J" last="Kish">S J Kish</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:7885342</idno><idno type="pmid">7885342</idno><idno type="doi">10.1002/mds.870100104</idno><idno type="wicri:Area/PubMed/Corpus">001936</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001936</idno><idno type="wicri:Area/PubMed/Curation">001936</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001936</idno><idno type="wicri:Area/PubMed/Checkpoint">001936</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001936</idno><idno type="wicri:Area/Ncbi/Merge">002422</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy.</title><author><name sortKey="Zhong, X H" sort="Zhong, X H" uniqKey="Zhong X" first="X H" last="Zhong">X H Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Haycock, J W" sort="Haycock, J W" uniqKey="Haycock J" first="J W" last="Haycock">J W Haycock</name></author><author><name sortKey="Shannak, K" sort="Shannak, K" uniqKey="Shannak K" first="K" last="Shannak">K. Shannak</name></author><author><name sortKey="Robitaille, Y" sort="Robitaille, Y" uniqKey="Robitaille Y" first="Y" last="Robitaille">Y. Robitaille</name></author><author><name sortKey="Fratkin, J" sort="Fratkin, J" uniqKey="Fratkin J" first="J" last="Fratkin">J. Fratkin</name></author><author><name sortKey="Koeppen, A H" sort="Koeppen, A H" uniqKey="Koeppen A" first="A H" last="Koeppen">A H Koeppen</name></author><author><name sortKey="Hornykiewicz, O" sort="Hornykiewicz, O" uniqKey="Hornykiewicz O" first="O" last="Hornykiewicz">O. Hornykiewicz</name></author><author><name sortKey="Kish, S J" sort="Kish, S J" uniqKey="Kish S" first="S J" last="Kish">S J Kish</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Dopa Decarboxylase (analysis)</term><term>Dopa Decarboxylase (metabolism)</term><term>Dopamine (analysis)</term><term>Dopamine (metabolism)</term><term>Humans</term><term>Immunoblotting</term><term>Middle Aged</term><term>Olivopontocerebellar Atrophies (diagnosis)</term><term>Olivopontocerebellar Atrophies (enzymology)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (enzymology)</term><term>Tyrosine 3-Monooxygenase (analysis)</term><term>Tyrosine 3-Monooxygenase (metabolism)</term><term>Visual Cortex (chemistry)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Dopa Decarboxylase</term><term>Dopamine</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopa Decarboxylase</term><term>Dopamine</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Visual Cortex</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Olivopontocerebellar Atrophies</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Olivopontocerebellar Atrophies</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Humans</term><term>Immunoblotting</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We measured the levels of dopamine, tyrosine hydroxylase (TH) protein, and dihydroxyphenylalanine (DOPA) decarboxylase (DDC) protein in the striatum of 10 patients with idiopathic Parkinson's disease (PD) and 23 patients with dominantly inherited olivopontocerebellar atrophy (OPCA). The levels of dopamine were markedly reduced (2% of control) in the striatum of the patients with PD, whereas striatal dopamine in the patients with OPCA ranged from normal (> 60% of control) to moderately reduced (20-60% of control) to severely depleted (< 20% of control). Both TH and DDC protein levels were significantly lower than those of the controls in the striatum of all of the patients with PD and in the subgroup of patients with OPCA having severely depleted dopamine. In contradistinction, TH but not DDC protein levels were reduced in those patients with OPCA having moderately reduced dopamine levels. This suggests that in the early stage of nigrostriatal dopamine neurone degeneration, DDC levels may be less susceptible to neurodegenerative influences than is TH synthesis or, alternatively, DDC synthesis may be more aggressively upregulated. Unexpectedly, from the blot immunolabeling analysis an additional DDC-immunoreactive band of slightly lower apparent molecular mass was detected in two of the patients with PD and in 12 of the patients with OPCA. This additional DDC band, which was not present in any of the control subjects, may reflect posttranslational modification(s) of DDC related to the neurodegenerative process.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7885342</PMID><DateCreated><Year>1995</Year><Month>04</Month><Day>13</Day></DateCreated><DateCompleted><Year>1995</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>1995</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy.</ArticleTitle><Pagination><MedlinePgn>10-7</MedlinePgn></Pagination><Abstract><AbstractText>We measured the levels of dopamine, tyrosine hydroxylase (TH) protein, and dihydroxyphenylalanine (DOPA) decarboxylase (DDC) protein in the striatum of 10 patients with idiopathic Parkinson's disease (PD) and 23 patients with dominantly inherited olivopontocerebellar atrophy (OPCA). The levels of dopamine were markedly reduced (2% of control) in the striatum of the patients with PD, whereas striatal dopamine in the patients with OPCA ranged from normal (> 60% of control) to moderately reduced (20-60% of control) to severely depleted (< 20% of control). Both TH and DDC protein levels were significantly lower than those of the controls in the striatum of all of the patients with PD and in the subgroup of patients with OPCA having severely depleted dopamine. In contradistinction, TH but not DDC protein levels were reduced in those patients with OPCA having moderately reduced dopamine levels. This suggests that in the early stage of nigrostriatal dopamine neurone degeneration, DDC levels may be less susceptible to neurodegenerative influences than is TH synthesis or, alternatively, DDC synthesis may be more aggressively upregulated. Unexpectedly, from the blot immunolabeling analysis an additional DDC-immunoreactive band of slightly lower apparent molecular mass was detected in two of the patients with PD and in 12 of the patients with OPCA. This additional DDC band, which was not present in any of the control subjects, may reflect posttranslational modification(s) of DDC related to the neurodegenerative process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>X H</ForeName><Initials>XH</Initials><AffiliationInfo><Affiliation>Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haycock</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Shannak</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Robitaille</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Fratkin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Koeppen</LastName><ForeName>A H</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Hornykiewicz</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Kish</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS26034</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.-</RegistryNumber><NameOfSubstance UI="D004296">Dopa Decarboxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004296" MajorTopicYN="N">Dopa Decarboxylase</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009849" MajorTopicYN="N">Olivopontocerebellar Atrophies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014793" MajorTopicYN="N">Visual Cortex</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7885342</ArticleId><ArticleId IdType="doi">10.1002/mds.870100104</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Fratkin, J" sort="Fratkin, J" uniqKey="Fratkin J" first="J" last="Fratkin">J. Fratkin</name><name sortKey="Haycock, J W" sort="Haycock, J W" uniqKey="Haycock J" first="J W" last="Haycock">J W Haycock</name><name sortKey="Hornykiewicz, O" sort="Hornykiewicz, O" uniqKey="Hornykiewicz O" first="O" last="Hornykiewicz">O. Hornykiewicz</name><name sortKey="Kish, S J" sort="Kish, S J" uniqKey="Kish S" first="S J" last="Kish">S J Kish</name><name sortKey="Koeppen, A H" sort="Koeppen, A H" uniqKey="Koeppen A" first="A H" last="Koeppen">A H Koeppen</name><name sortKey="Robitaille, Y" sort="Robitaille, Y" uniqKey="Robitaille Y" first="Y" last="Robitaille">Y. Robitaille</name><name sortKey="Shannak, K" sort="Shannak, K" uniqKey="Shannak K" first="K" last="Shannak">K. Shannak</name></noCountry><country name="Canada"><noRegion><name sortKey="Zhong, X H" sort="Zhong, X H" uniqKey="Zhong X" first="X H" last="Zhong">X H Zhong</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002422 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002422 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:7885342
|texte= Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:7885342" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |